|
|
||||||||
Departments of 1 Physiology and Biophysics, 2 Surgery, and 3 Hematology, Mayo Clinic and Foundation, Rochester, Minnesota 55905
| |
ABSTRACT |
|---|
|
|
|---|
Experiments were designed to determine
how ovariectomy modulates mitogenic factors in platelets and how these
factors affect proliferation of coronary arterial smooth muscle.
Platelet-derived growth factors (PDGFAB and
PDGFBB), transforming growth factors (TGF-
1
and TGF-
2), and vascular endothelial growth factor
(VEGF165) were quantified in platelet lysates and
platelet-poor plasma from adult gonadally intact and ovariectomized
female pigs by ELISA. Proliferation of cultured coronary arterial
smooth muscle cells (SMCs) from both groups of pigs was determined in
response to autologous or heterologous platelet lysates. Platelet
concentrations of PDGFBB, but not PDGFAB,
TGF-
1, and TGF-
2, increased with ovariectomy. VEGF165 was not detected in platelets from
either group. Proliferation of SMCs from ovariectomized females was
significantly greater on exposure to autologous or heterologous
platelet lysates than proliferation of SMCs from intact females. These
results indicate that ovariectomy increases concentrations of
PDGFBB in platelets. Higher levels of PDGFBB in
platelets in synergy with other platelet-derived products could
contribute to increased proliferative arterial response to injury after ovariectomy.
estrogen; hormone; megakaryocytes; platelet-derived growth factor; transforming growth factor
| |
INTRODUCTION |
|---|
|
|
|---|
PLATELETS ARE ESSENTIAL for hemostasis after vascular injury. At sites of vascular injury, aggregating platelets release factors that have vasoactive and mitogenic properties (2, 14, 34). In the absence of intact or functional endothelium, these factors cause contraction of vascular smooth muscle (32, 41), recruitment of more platelets and other blood cells, cholesterol synthesis (13), low-density lipoprotein receptor expression (45), and proliferation and migration of vascular smooth muscle cells (SMCs) from the media to the intima layer of the vessel wall (11, 15). All of these actions also contribute to arterial occlusive disease (22, 36, 38).
Epidemiological studies indicate that the incidence of coronary artery
disease (CAD) is lower in premenopausal women compared with age-matched
men (7). However, the incidence of CAD increases with
menopause, but the risk is decreased in healthy postmenopausal women
taking estrogen replacement (28). These observations
suggest that ovarian hormones, in particular 17
-estradiol, may be
protective against development of CAD in women.
Ovarian hormones may affect platelet function. Ovariectomy increases
prostacyclin content in platelets from female pigs (26). Incubating platelets from postmenopausal women with 17
-estradiol inhibits ADP-mediated platelet aggregation and ATP release
(4). Platelets release platelet-derived growth factors
(PDGFs) and transforming growth factors (TGFs) on platelet activation
(1, 11). Both platelet-derived factors are involved in
modulating cell migration, proliferation, and extracellular matrix
production by SMCs. However, it is unknown whether ovarian hormones
affect concentrations of growth factors in platelets. Therefore,
experiments were designed to test the hypothesis that ovariectomy (loss
of ovarian hormones to mimic menopause) increases content of
PDGFAB, PDGFBB, TGF-
1,
TGF-
2, and vascular endothelial growth factor (VEGF165) in platelets and, furthermore, as a consequence
of such increase, that the proliferative response of vascular SMCs
would increase to platelet-lysate from ovariectomized (Ovx) pigs
compared with lysate from ovary-intact pigs.
| |
METHODS |
|---|
|
|
|---|
Animal and tissue collection. Adult (6 mo old, 110-120 kg) gonadally intact and Ovx (for 4 wk) female Yorkshire pigs were used for this study. Ovariectomy was by laparoscopy. Sham laparoscopy surgeries were also performed in age-matched, gonadally intact female pigs to determine the effects of laparoscopy surgery on platelets. Pigs were housed individually (22°C; 12:12-h light-dark cycle) and were fed twice a day (Lean Grow 93, Land O' Lakes Farmland Feed; Fort Dodge, IA). The external genitalia from gonadally intact females showed changes associated with an estrus cycle. Serum levels of estrogen from gonadally intact females range from 10 to 30 pg/ml, and estrogen levels in Ovx females are below the sensitivity level of assay (6, 43). Uterine weight from Ovx females was significantly lower compared with uterine weight from gonadally intact females (51.3 ± 7.8 vs. 86.6 ± 12.3), thus validating efficacy of the surgical intervention. Four week after surgery, Ovx and age-matched gonadally intact pigs were anesthetized intramuscularly with ketamine (8 mg/kg) and xylazine (12 mg/kg). Blood (450 ml) was collected aseptically (22°C) from the right carotid artery directly into collecting bags (Baxter Healthcare) containing 50 ml of acid citrate-dextrose (ACD) solution (pH 6.5, 1:9 vol/vol). Blood (45 ml) was collected (from the femoral artery) before and 4 wk after ovariectomy into polypropylene tubes containing 5 ml ACD solution (pH 6.5, 1:9 vol/vol) for determination of the number of peripheral platelets, red blood cells, white blood cells, hematocrit, and hemoglobin by a Coulter Gen-S hematology analyzer. Bone marrow was biopsied from the ribs using an 8-gauge × 4-in. bone biopsy needle (Medical Device Technologies). Coronary arteries were removed for tissue culture.
Reticulated platelets. The percentage of reticulated platelets [youngest platelets in circulation containing mRNA (17)] was measured to obtain an indication of platelet turnover before and 4 wk after surgery. A 19-gauge needle was inserted into an ear vein. Blood was allowed to drip, and 20 µl of blood were collected and added to 2 ml of the following dilution buffer (22°C): 20 mol/l HEPES, Hank's balanced salts (Sigma) (pH 7.4), supplemented with 1 mg/ml bovine serum albumin (BSA), 1 µmol/l tick anticoagulant peptide, 25 nM Hirudin, and 1 µg/ml PGE1 (Sigma). All concentrations are final concentrations in the dilution medium. Samples were incubated for 30 min in the dark (22°C) with a porcine GP Ib-biotin-conjugated monoclonal mouse antibody. Streptavidin-phycoerythrin (10 µl)-conjugated antibody was then added for 30 min (in the dark, 22°C). Afterward, control tubes received 1 ml of 1× PBS. The other tubes received 1 ml thiazole orange at 20 ng/ml. Tubes were incubated in the dark for 30 min (22°C). Dilution buffer (1 ml) was added to each tube, and the tubes were centrifuged (3,000 rpm, 15 min, 22°C). Supernatants were removed, and the pellets were resuspended gently in 2 ml of 1× PBS. Platelets were quantified by flow cytometry (FACcalibur, Becton-Dickinson) within 2 h. Log forward scatter (for size characteristic) and log side scatter (for granularity) were used to identify platelets. The platelet cloud was gated electronically to exclude red and white blood cells.
Immunofluorescence and immunohistochemical stainings for estrogen
receptor-
and -
in porcine platelets and bone marrow biopsies,
respectively.
ACD + 0.1% BSA-washed platelets were smeared on
poly-L-lysine-covered slides, air dried, and fixed with
buffered formalin-acetone for 30 s. Rib bone marrow biopsies were
fixed in 10% formalin, paraffin embedded, sectioned (3 µm), and
mounted on glass slides. Slides were incubated for 30 min with 20%
normal goat or rabbit serum (Vector Laboratories, diluted in 1× PBS).
Excess serum was blotted off, and slides were incubated overnight at
4°C with either affinity-purified primary polyclonal rabbit antibody
against estrogen receptor (ER)-
(1:200 in 1× PBS, Santa Cruz
Biotechnology) + 20% normal goat serum or with affinity-purified
primary polyclonal goat antibody against ER-
(1:200 in 1× PBS,
Santa Cruz Biotechnology) + 20% normal rabbit serum. Slides were
then washed three times (5 min, 1× PBS). Platelets were incubated for
30 min in the dark with either affinity-purified fluorescein goat
anti-rabbit or flourescein rabbit anti-goat antibodies (in 1× PBS + 20% serum). Slides were rinsed with 1× PBS (3 times), and platelets
were mounted with ProLong antifade reagent (Molecular Probes), covered
with a glass coverslip, and visualized with a confocal microscope. Bone
marrow biopsies were incubated (30 min) with biotinylated secondary
goat anti-rabbit or rabbit anti-goat IgG antibodies. Peroxidase
activity in bone marrow biopsies was visualized with a diaminobenzidine
tetrahydrochloride substrate kit (Vector Laboratories) for 2 min.
Control stainings were obtained by treating slides similarly with the
above procedures with the exception of omitting primary antibodies for
either ER-
or ER-
.
Preparation of platelet lysate.
Blood from the right carotid artery collected into sterile collecting
bags was centrifuged at 300 g (22°C, 15 min).
Platelet-rich plasma was collected into polypropylene tubes and
centrifuged at 1,600 g (22°C, 10 min) to precipitate
platelets. Platelet-poor plasma (PPP) was removed and stored at
70°C. Precipitated platelet pellets were washed and resuspended
with an equal volume of ACD solution + 0.3% BSA. The platelet
count was obtained, and afterward platelets were precipitated (1,600 g, 10 min, 22°C) and resuspended to adjusted platelet
concentration to 1 × 109 platelets/ml in 1× PBS
(calcium and magnesium free, 22°C, Sigma) + 0.1% BSA. Aliquots
were frozen and stored at
70°C. Platelets were lysed on thawing.
Concentrations of PDGFAB, PDGFBB,
TGF-
1, TGF-
2, and VEGF165
were determined by ELISA in PPP and platelet lysate.
Quantitating growth factors in platelet lysates by ELISA.
Concentrations of PDGFAB, PDGFBB,
TGF-
1, TGF-
2, and VEGF165 in
platelets and PPP were determined by commercially available human ELISA
kits (R&D Systems). All samples were assayed in duplicate. PDGFAB ELISA has 10 and 2% cross-reactivity with
PDGFAA and PDGFBB, respectively.
PDGFBB ELISA has 0.1% cross-reactivity with
PDGFAB. TGF-
1, TGF-
2, and
VEGF165 immunoassays have no significant cross-reactivity or interference with other growth factors.
Coronary artery SMC cultures.
SMCs from the right coronary artery were isolated via the explant
method (27). SMCs stained positive for
-actin, myosin heavy chain, vimentin, and desmin (Sigma). Forty thousand SMCs per
milliliter, third passage, were suspended in phenol red-free M199
(Sigma) with 10% charcoal-stripped fetal bovine serum (CS-FBS, Atlanta
Biologicals) and plated in 24-well polystyrene plates (37°C, 95%
air-5% CO2 atmosphere). Twenty-four hours later, cells were growth arrested in serum-free medium 199 (M199) for 24 h before the addition of platelet lysate. Platelet lysates prepared from
1 × 109 SMCs/ml diluted with 2% CS-FBS M199 to
obtain platelet lysate concentrations ranging from 0.25 to 50% were
then added to the cultures. For controls, cells were incubated
with 2% CS-FBS (control) or 2% CS-FBS + 1.5% 1× PBS (calcium
and magnesium free, 50:50) to control the concentration of 1× PBS in
the 50% dilution of platelet lysates. Six hours after the addition of
lysate or control solutions, [3H]thymidine (1 µCi/well)
was added to the cultures. After an additional 18 h (24-h exposure
to platelet lysates or control solutions), SMCs were rinsed twice with
cold 1× PBS, incubated with cold trichloroacetic acid for 12 min,
digested with 0.1 N NaOH for 5 min, and frozen. The digested cell
preparation was thawed once to analyze the [3H]thymidine
incorporation by scintillation spectroscopy (Beckman Instruments).
Protein concentration was determined by the Bradford assay (Bio-Rad).
All experiments were conducted in quadruplicate.
Conditioned cell medium from coronary artery SMC cultures.
Forty thousand SMCs per milliliter, third passage, suspended in phenol
red-free M199 with 10% CS-FBS were plated in 24-well plates. After
24 h, cells were growth arrested by incubating them in serum-free
M199. Twenty-four hours after growth arrest, 2% CS-FBS-M199 was added
to the cultures. After 24 h, the conditioned media was collected
and centrifuged to remove any cells, and concentrations of
PDGFAB, PDGFBB, TGF-
1,
TGF-
2, and VEGF165 were measured by human
ELISA kits (R&D Systems). The same growth factors were measured by
ELISA in 2% CS-FBS-M199 incubated in the plates but in the absence of SMCs.
Statistical analysis. All data are expressed as means ± SE; n equals the number of pigs from which platelets were collected. For proliferation experiments, the mean of quadruplicate measures were used for a single experiment, and n equals the number of pigs from which cells were derived for each experiment. Student's t-test (two tailed) for paired or unpaired data was used to assess statistical significance. One-way ANOVA followed by Bonferroni's post hoc analysis was used to compare more than two means. For all statistical tests, P < 0.05 was considered statistically significant.
| |
RESULTS |
|---|
|
|
|---|
Peripheral blood cell number and reticulated platelets.
Sham surgery did not significantly change total circulating platelets,
percentage of reticulated platelets, or red blood cell and lymphocyte
numbers (Table 1). Circulating numbers of
platelets and reticulated platelets as percentages of total
platelet number were not significantly changed with ovariectomy.
However, the number of circulating red blood cells, hemoglobin, and
hematocrit was significantly higher in Ovx animals compared with
gonadally intact females (Table 1). Ovx females had a significantly
lower number of circulating lymphocytes (Table 1). These results
indicate that loss of ovarian hormones but not surgical intervention
affects blood elements.
|
Immunohistochemistry in bone marrow biopsies.
Megakaryocytes, the largest and polymorphic nuclear cells in the bone
marrow producing platelets from their cytoplasmic fragmentation, stained positive for ER-
(Fig.
1A) and
ER-
(Fig. 1B). Nuclear and cytoplasmic stainings for ERs
were observed in megakaryocytes from both groups. Positive staining for
ER-
and ER-
was not exclusive to megakaryocytes because other
cells in bone marrow also stained positive for both receptors. No
staining was observed in the absence of primary antibodies for either
ER-
(Fig. 1C) or ER-
(Fig. 1D).
|
Immunofluorescence staining for ERs in female porcine platelets.
Platelets from gonadally intact and Ovx female pigs showed positive
immunofluorescent staining for ER-
(Fig.
2A) and ER-
(Fig.
2B). A greater number of platelets stained positive for ER-
in both groups of animals, with only a few platelets staining positive for ER-
. No immunofluorescence was observed in the absence of primary antibody (data not shown, n = 4).
|
Concentration of growth factors in platelets and PPP.
Concentrations of PDGFAB were similar in lysates from
1 × 109 platelets/ml from gonadally intact
(1,676 ± 183.6 pg/ml, n = 12) and Ovx (1,220 ± 134.7 pg/ml, n = 12) female pigs. However, concentrations of PDGFBB increased significantly in
platelet lysates with ovariectomy (Fig.
3).
|
1 and TGF-
2 in
platelet lysates did not change with ovariectomy (Fig.
4); concentrations of VEGF165 were below the sensitivity level of the assay (9.0 pg/ml).
|
1 in PPP from Ovx female pigs were greater than
those in PPP from intact females (Table
2). However, VEGF165 was
detected only in PPP from gonadally intact female pigs. Therefore,
ovariectomy differentially affects the concentration of growth
factors in platelets and plasma.
|
Proliferation of coronary artery SMCs in response to platelet
lysate.
Proliferation of right coronary arterial SMCs from gonadally intact and
Ovx female pigs treated with 2% CS-FBS-M199 only (control) were
similar (Fig. 5). Treating SMCs from both
groups with 1× PBS + 2% CS-FBS-M199 inhibited their
proliferation. However, adding 2% CS-FBS-M199 + platelet lysates
(containing 1× PBS) restored SMC proliferation in both groups.
Treating SMCs from both groups with 0.25-1.5% of autologous
platelet lysates increased their proliferation by ~1.5-fold (data not
shown). Incubating SMCs from Ovx females with 6.5%, 12.5%, and 25%
of autologous platelet lysates (from 1 × 109
platelets/ml) significantly increased SMC proliferation 1.5- to
2.5-fold compared with controls (Fig. 5B). A 1.5- to 2-fold increase was observed in proliferation of SMCs from intact females (Fig. 5A) when treated with 1.5-12.5% of autologous
platelet lysates. However, treating SMCs from intact females with 25%
of autologous platelet lysates decreased their proliferation back to
control levels, and treatment with 50% of autologous platelet lysates completely inhibited their proliferation. Incubating SMCs from Ovx
females with 25-50% of autologous platelet lysates produced a
2.5- and 1.5-fold SMC growth, respectively, in their proliferation (Fig. 5B). These results suggest that mitogenic factors in
platelet lysates from Ovx females increase proliferation of SMCs to a
greater extent than lysates from intact females. However, to determine whether responsiveness of SMCs affected responses to platelet lysates,
SMCs from gonadally intact females were treated with lysate from
platelets of Ovx females, and SMCs from Ovx females were treated with
lysate from platelets of intact females. Variable cell proliferation at
different platelet lysate concentrations was observed (Fig.
6). However, unlike proliferation to
autologous platelet lysate, treating SMCs of intact females with the
highest concentrations (25% and 50%) of platelet lysates from Ovx
females increased proliferation. Treating SMCs from Ovx females with
either autologous platelet lysate or lysate from gonadally intact
female platelets increased proliferation twofold (Fig. 6). These
results suggest that both platelet content of growth factors and SMCs are affected by ovariectomy.
|
|
Concentrations of growth factors in media conditioned by
SMCs.
Concentrations of TGF-
1 and VEGF165,
but not PDGFAB, were significantly higher in media
conditioned by SMCs from Ovx female pigs than in media conditioned by
SMCs from intact female pigs (Table 3).
Levels of PDGFBB and TGF-
2 were not detected
in media conditioned by either groups of cells (n = 3, data not shown). These results indicate that SMCs release growth
factors that could alter proliferation as autocrine hormones.
|
| |
DISCUSSION |
|---|
|
|
|---|
Results from the present study indicate that removal of ovarian hormones by ovariectomy increases content of growth factors, particularly PDGFBB, in platelets without altering the total circulating platelet number and percentage of reticulated platelets.
Because platelets do not have a nucleus, only residual amounts of mRNA,
and limited protein synthesis (9), the presence of ER-
and ER-
in megakaryocytes (in the nucleus and cytoplasm) from both
groups indicates that ovarian hormones, including 17
-estradiol, may
be involved in modulating content of growth factors genomically in
megakaryocytes. ER-
may be the main ER in porcine platelets because
platelets from both groups had more extensive positive immunofluorescence staining to ER-
than to ER-
. These results are
consistent with results from studies on human platelets because only
ER-
, but not ER-
, has been detected (19). With the
use of Western blotting as a more quantitative measure of ER
distribution, recent studies from our laboratory have extended these
immunofluorescent data and found that both ER-
and ER-
are
upregulated with ovariectomy (18). Therefore, in addition
to regulation of growth factors in platelets by ovarian hormones, ERs
themselves are regulated.
Because platelets first respond to vascular injury (37)
and are involved in the development of CAD (35, 42), these
results have implications to explain differences in presentation of CAD after menopause. 17
-Estradiol, the main ovarian hormone in
premenopausal women, may protect against risks for CAD by reducing
content of mitogenic factors in platelets (10). For
example, platelets aggregating in response to arterial injury or
endothelial dysfunction would release increased amounts of
PDGFBB and in combination with other factors
synergistically increase proliferation of SMCs in Ovx or
estrogen-depleted animals. SMC proliferation may not be arrested by
TGF-
(25, 33), because similar levels were observed in
platelet lysates from ovary-intact and Ovx animals. TGF-
inhibit growth of vascular SMCs. It has been hypothesized that atherosclerosis may result from a failure in endogenous inhibitory systems that normally limit wound repair (23).
Growth factors released from SMCs may also contribute to the response
to injury because autocrine and paracrine factors from media
conditioned with SMCs from Ovx females had higher TGF-
1 and VEGF165 levels than media conditioned by cells from
ovary-intact animals. VEGF165 may act as a paracrine
hormone to stimulate migration and proliferation of endothelial
cells (21). However, TGF-
1 may induce
VEGF165 expression (8) and synergistically
with TGF-
1 may increase vascular SMC proliferation
(44). Modulation and release of other growth factors
[insulin-like growth factor (IGF)-I] in platelets and SMCs from Ovx
female porcines cannot be excluded. However, proliferation of vascular
SMCs treated with combinations of PDGFBB, IGF-I, epidermal
growth factor, and TGF-
was not further increased compared with SMCs
treated with PDGFBB only (16). In addition,
higher plasma concentrations of circulating PDGF activity are observed
in patients with severe CAD compared with age- and sex-matched controls
(29, 30).
17
-Estradiol inhibits migration/proliferation of vascular SMCs
(20, 24, 39). Ovx female pigs have significantly lower levels of 17
-estradiol compared with gonadally intact female pigs
(6). The high concentrations of PDGFAB,
PDGFBB, and TGF-
1 and lower levels of
VEGF165 in plasma from Ovx females and higher concentrations of PDGFBB that could be released from
platelets may synergistically contribute to an increased response to
injury (34) and stimulate growth of SMCs at the vascular
wall in the absence or low levels of ovarian hormones.
Ovariectomy increased circulating numbers of red blood cells. These cells traveling in the axis of the artery force platelets toward the endothelial lining, increasing platelet-platelet and platelet-endothelial contact (12) as well as increasing blood viscosity. ADP released from red blood cells could activate platelets (3, 40) and contribute to platelet recruitment at the vessel wall.
Differences in platelet irritability between gonadally intact and Ovx female pigs were not determined in the present study. Platelet aggregation and ATP release in vitro are higher in platelets from postmenopausal women than in platelets from premenopausal women (4, 5). Furthermore, in addition to ERs being upregulated by ovariectomy, chaperone proteins of the heat shock family known to regulate nitric oxide and nitric oxide synthase are also upregulated by depletion of ovarian hormones (18). Therefore, interaction between platelet-derived nitric oxide and endothelium-derived nitric oxide will also affect platelet aggregation and secretion at sites of injury and endothelial dysfunction.
In conclusion, removal of ovarian hormones does not affect the number
of platelets but increases the number of red blood cells and decreases
the number of circulating lymphocytes that could contribute to
development of increased arterial response to injury by increasing
blood viscosity, platelet-platelet activation, and platelet-endothelial
cell interaction. In addition, levels of mitogenic growth factors in
plasma are increased with ovariectomy, as is the content of
PDGFBB in platelets. Therefore, release of platelet
PDGFBB and blood-derived growth factors as well as growth factors produced by SMCs could contribute to migration, proliferation, and synthesis of extracellular matrix proteins by SMCs that ultimately participate in the development of intimal thickening associated with
response to injury and development of CAD, as observed in Ovx animals
and postmenopausal women, respectively (31). The presence
of ER-
and ER-
in platelets and bone marrow megakaryocytes suggests that 17
-estradiol may modulate PDGFBB levels
genomically in megakaryocytes. The ERs on circulating platelets
could affect nongenomic release of factors or other platelet functions
when hormones are placed into ovarian hormone-deficient animals or humans.
| |
FOOTNOTES |
|---|
Address for reprint requests and other correspondence: V. M. Miller, Dept. of Surgery, Mayo Clinic and Foundation, 200 First St. SW, Rochester, MN 55905 (E-mail: miller.virginia{at}mayo.edu).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
May 2, 2002;10.1152/ajpheart.00201.2002
Received 7 March 2002; accepted in final form 29 April 2002.
| |
REFERENCES |
|---|
|
|
|---|
1.
Abdelouahed, M,
Ludlow A,
Brunner G,
and
Lawler J.
Activation of platelet-transforming growth factor beta-1 in the absence of thrombospondin-1.
J Biol Chem
275:
17933-17936,
2000
2.
Amoroso, G,
van Veldhuisen DJ,
Tio RA,
and
Mariani M.
Pathophysiology of vascular endothelium and circulating platelets: implications for coronary revascularization and treatment.
Int J Cardiol
79:
265-275,
2001[ISI][Medline].
3.
Andrews, DA,
and
Low PS.
Role of red blood cells in thrombosis.
Curr Opin Hematol
6:
76-82,
1999[Medline].
4.
Bar, J,
Lahav J,
Hod M,
Ben-Rafael Z,
Weinberger I,
and
Brosens J.
Regulation of platelet aggregation and adenosine triphosphate release in vitro by 17beta-estradiol and medroxyprogesterone acetate in postmenopausal women.
Thromb Haemost
84:
695-700,
2000[ISI][Medline].
5.
Bar, J,
Tepper R,
Fuchs J,
Pardo Y,
Goldberger S,
and
Ovadia J.
The effect of estrogen replacement therapy on platelet aggregation and adenosine triphosphate release in postmenopausal women.
Obstet Gynecol
81:
261-264,
1993
6.
Barber, DA,
and
Miller VM.
Gender differences in endothelium-dependent relaxations do not involve NO in porcine coronary arteries.
Am J Physiol Heart Circ Physiol
273:
H2325-H2332,
1997
7.
Barrett-Connor, E,
and
Bush TL.
Estrogen and coronary heart disease in women.
JAMA
265:
1861-1867,
1991[Abstract].
8.
Breier, G,
Blum S,
Peli J,
Groot M,
Wild C,
Risau W,
and
Reichmann E.
Transforming growth factor-beta and Ras regulate the VEGF/VEGF-receptor system during tumor angiogenesis.
Int J Cancer
97:
142-148,
2002[ISI][Medline].
9.
Brown, AS,
and
Martin JF.
The megakaryocyte platelet system and vascular disease.
Eur J Clin Invest
1:
9-15,
1994.
10.
Chen, Z,
Yuhanna IS,
Galcheva-Gargova Z,
Karas RH,
Mendelsohn ME,
and
Shaul PW.
Estrogen receptor alpha mediates the nongenomic activation of endothelial nitric oxide synthase by estrogen.
J Clin Invest
103:
401-406,
1999[ISI][Medline].
11.
Durante, W,
Liao L,
Iftikhar I,
Cheng K,
and
Schafer AI.
Platelet-derived growth factor regulates vascular smooth muscle cell proliferation by inducing cationic amino acid transporter gene expression.
J Biol Chem
271:
11838-11843,
1996
12.
Goldsmith, HL,
Bell DN,
Braovac S,
Steinberg A,
and
McIntosh F.
Physical and chemical effects of red cells in the shear-induced aggregation of human platelets.
Biophys J
69:
1584-1595,
1995
13.
Habenicht, AJ,
Glomset JA,
and
Ross R.
Relation of cholesterol and mevalonic acid to the cell cycle in smooth muscle and swiss 3T3 cells stimulated to divide by platelet-derived growth factor.
J Biol Chem
255:
5134-5140,
1980
14.
Harker, LA,
Ross R,
Slichter SJ,
and
Scott CR.
Homocystine-induced arteriosclerosis. The role of endothelial cell injury and platelet response in its genesis.
J Clin Invest
58:
731-741,
1976[ISI][Medline].
15.
Hughes, AD,
Clunn GF,
Refson J,
and
Demoliou-Mason C.
Platelet-derived growth factor (PDGF): actions and mechanisms in vascular smooth muscle.
Gen Pharmacol
27:
1079-1089,
1996[ISI][Medline].
16.
Hwang, DL,
Latus LJ,
and
Lev-Ran A.
Effects of platelet-contained growth factors (PDGF, EGF, IGF-1, and TGF-
) on DNA synthesis in porcine aortic smooth muscle cells in culture.
Exp Cell Res
200:
358-360,
1992[ISI][Medline].
17.
Ingram, M,
and
Coopersmith A.
Reticulated platelets following acute blood loss.
Brit J Hematol
17:
225-229,
1969[ISI][Medline].
18.
Jayachandran, M,
and
Miller VM.
Ovariectomy upregulates expression of estrogen receptors, NOS, and HSPs in porcine platelets.
Am J Physiol Heart Circ Physiol
283:
H220-H226,
2002
19.
Khetawat, G,
Faraday N,
Nealen ML,
Vijayan KV,
Bolton E,
Noga SJ,
and
Bray PF.
Human megakaryocytes and platelets contain the estrogen receptor
and androgen receptor (AR): testosterone regulates AR expression.
Blood
95:
2289-2296,
2000
20.
Kolodgie, FD,
Jacob A,
Wilson PS,
Carlson GC,
Farb A,
Verma A,
and
Virmani R.
Estradiol attenuates directed migration of vascular smooth muscle cells in vitro.
Am J Pathol
148:
969-976,
1996[Abstract].
21.
Kronemann, N,
Bouloumi A,
Bassus S,
Kirchmaier CM,
Busse R,
and
Schini-Kerth VB.
Aggregating human platelets stimulate expression of vascular endothelial growth factor in cultured vascular smooth muscle cells through a synergistic effect of transforming growth factor-beta(1) and platelet-derived growth factor(AB).
Circulation
100:
855-860,
1999
22.
Kullo, IJ,
Gau GT,
and
Tajik AJ.
Novel risk factors for atherosclerosis.
Mayo Clin Proc
75:
369-380,
2000[ISI][Medline].
23.
McCaffrey, TA.
TGF-betas and TGF-beta receptors in atherosclerosis.
Cytokine Growth Factor Rev
11:
103-114,
2000[ISI][Medline].
24.
Mendelsohn, ME,
and
Karas RH.
The protective effects of estrogen on the cardiovascular system.
N Engl J Med
340:
1801-1811,
1999
25.
Mii, S,
Ware JA,
and
Kent KC.
Transforming growth factor-beta inhibits human vascular smooth muscle cell growth and migration.
Surgery
114:
464-470,
1993[ISI][Medline].
26.
Miller, VM,
Lewis DA,
and
Barber DA.
Gender differences and endothelium- and platelet-derived factors in the coronary circulation.
Clin Exp Pharmacol Physiol
26:
132-136,
1999[ISI][Medline].
27.
Moraghan, T,
Antoniucci DM,
Grenert JP,
Sieck GC,
Johnson C,
Miller VM,
and
Fitzpatrick LA.
Differential response in cell proliferation to beta estradiol in coronary artery vascular smooth muscle cells obtained from mature female versus male animals.
Endocrinology
137:
5174-5177,
1996[Abstract].
28.
Mosca, L,
Collins P,
Herrington DM,
Mendelsohn ME,
Pasternak RC,
Robertson RM,
Schenck-Gustafsson K,
Smith SC, Jr,
Taubert KA,
and
Wenger NK.
Hormone replacement therapy and cardiovascular disease: a statement for healthcare professionals from the American Heart Association.
Circulation
104:
499-503,
2001
29.
Nilsson, J,
Eluge G,
Wallin M,
Hampsten A,
and
Blomback M.
Correlation between plasma levels of growth factor and von Willebrand factor.
Thromb Res
54:
125-132,
1989[ISI][Medline].
30.
Nilsson, J,
Svensson J,
Hamsten A,
and
de Faire U.
Increased platelet derived mitogenic activity in plasma of young patients with coronary atherosclerosis.
Atherosclerosis
61:
237-243,
1986[ISI][Medline].
31.
O'Brien, JE,
Peterson ED,
Keeler GP,
Berdan LG,
Ohman EM,
Faxon DP,
Jacobs AK,
Topol EJ,
and
Califf RM.
Relation between estrogen replacement therapy and restenosis after percutaneous coronary interventions.
J Am Coll Cardiol
28:
1111-1118,
1996[Abstract].
32.
Pearson, PJ,
Schaff HV,
and
Vanhoutte PM.
Acute impairment of endothelium-dependent relaxations to aggregating platelets following reperfusion injury in canine coronary arteries.
Circ Res
67:
385-393,
1990
33.
Reddy, KB,
and
Howe PH.
Transforming growth factor beta 1-mediated inhibition of smooth muscle cell proliferation is associated with a late G1 cell cycle arrest.
J Cell Physiol
156:
48-55,
1993[ISI][Medline].
34.
Ross, R.
The pathogenesis of atherosclerosis-an update.
N Engl J Med
14:
488-500,
1986.
35.
Ross, R.
Platelet-derived growth factor.
Lancet
1:
1179-1182,
1989[ISI][Medline].
36.
Ross, R,
and
Glomset JA.
The pathogenesis of atherosclerosis.
N Engl J Med
295:
420-425,
1976[ISI][Medline].
37.
Ruggeri, ZM.
Mechanisms initiating platelet thrombus formation.
Thromb Haemost
78:
611-616,
1997[ISI][Medline].
38.
Schwartz, SM,
Virmani R,
and
Rosenfeld ME.
The good smooth muscle cells in atherosclerosis.
Curr Atherosclerosis Reports
2:
422-429,
2000.
39.
Suzuki, A,
Mizuno K,
Ino Y,
Okada M,
Kikkawa F,
Mizutani S,
and
Tomoda Y.
Effects of 17beta-estradiol and progesterone on growth-factor-induced proliferation and migration in human female aortic smooth muscle cells in vitro.
Cardiovasc Res
32:
516-523,
1996[ISI][Medline].
40.
Valles, J,
Santos MT,
Aznar J,
Marcus AJ,
Martinez-Sales V,
Portoles M,
Broekman MJ,
and
Safier LB.
Erythrocytes metabolically enhance collagen-induced platelet responsiveness via increased thromboxane production, adenosine diphosphate release, and recruitment.
Blood
78:
154-162,
1991
41.
Vanhoutte, PM.
Platelet-derived serotonin, the endothelium, and cardiovascular disease.
J Cardiovasc Pharmacol
5:
S6-S12,
1991.
42.
Vanhoutte, PM.
Endothelial dysfunction and atherosclerosis.
Eur Heart J
18:
E19-E29,
1997.
43.
Wang, X,
Barber DA,
Lewis DA,
McGregor CGA,
Sieck GA,
Fitzpatrick LA,
and
Miller VM.
Gender and transcriptional regulation of NO synthase and ET-1 in porcine aortic endothelial cells.
Am J Physiol Heart Circ Physiol
273:
H1962-H1967,
1997
44.
Williams, B.
Mechanical influences on vascular smooth muscle cell function.
J Hypertens
16:
1921-1929,
1998[ISI][Medline].
45.
Witte, LD,
and
Cornicelli JA.
Platelet-derived growth factor stimulates low density lipoprotein receptor activity in cultured human fibroblasts.
Proc Natl Acad Sci USA
77:
5962-5966,
1980
This article has been cited by other articles:
![]() |
M. Jayachandran and V. M. Miller Mechanisms of estrogenic vascular protection Am J Physiol Heart Circ Physiol, February 1, 2006; 290(2): H507 - H508. [Full Text] [PDF] |
||||
![]() |
E. Rzewuska-Lech, M. Jayachandran, L. A. Fitzpatrick, and V. M. Miller Differential effects of 17{beta}-estradiol and raloxifene on VSMC phenotype and expression of osteoblast-associated proteins Am J Physiol Endocrinol Metab, July 1, 2005; 289(1): E105 - E112. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Jayachandran, K. Karnicki, R. S. Miller, W. G. Owen, K. S. Korach, and V. M. Miller Platelet Characteristics Change With Aging: Role of Estrogen Receptor {beta} J. Gerontol. A Biol. Sci. Med. Sci., June 1, 2005; 60(7): 815 - 819. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Jayachandran, R. Mukherjee, T. Steinkamp, P. LaBreche, M. P. Bracamonte, H. Okano, W. G. Owen, and V. M. Miller Differential effects of 17{beta}-estradiol, conjugated equine estrogen, and raloxifene on mRNA expression, aggregation, and secretion in platelets Am J Physiol Heart Circ Physiol, May 1, 2005; 288(5): H2355 - H2362. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Jayachandran, H. Okano, R. Chatrath, W. G. Owen, J. P. McConnell, and V. M. Miller Sex-specific changes in platelet aggregation and secretion with sexual maturity in pigs J Appl Physiol, October 1, 2004; 97(4): 1445 - 1452. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Jayachandran, W. G. Owen, and V. M. Miller Effects of ovariectomy on aggregation, secretion, and metalloproteinases in porcine platelets Am J Physiol Heart Circ Physiol, May 1, 2003; 284(5): H1679 - H1685. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |